<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020540</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068601</org_study_id>
    <secondary_id>NCI-01-C-0121</secondary_id>
    <secondary_id>NCI-1035</secondary_id>
    <nct_id>NCT00020540</nct_id>
    <nct_alias>NCT00012532</nct_alias>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer</brief_title>
  <official_title>Treatment Of Patients With Metastatic Melanoma And Renal Cancer With A Combination Of Flt3L And CD40L</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate&#xD;
      the immune system and stop cancer cells from growing. Biological therapy may be an effective&#xD;
      treatment for metastatic melanoma and metastatic kidney cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of flt3L combined with CD40-ligand in&#xD;
      treating patients who have metastatic melanoma or metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of CD40-ligand when combined with&#xD;
      fixed-dose flt3 ligand in patients with metastatic melanoma or renal cell cancer.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of CD40-ligand. Patients receive fixed-dose flt3&#xD;
      ligand subcutaneously (SC) daily on days 1-14 and CD40-ligand SC daily on days 12-16.&#xD;
      Treatment continues every 28 days for a maximum of 6 courses in the absence of unacceptable&#xD;
      toxicity or disease progression. Cohorts of 3 to 6 patients receive escalating doses of&#xD;
      CD40-ligand until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients with&#xD;
      progressive disease after 2 courses may be eligible to receive high-dose interleukin-2 (IL-2)&#xD;
      standard therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5 patients were accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant CD40-ligand</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant flt3 ligand</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed metastatic renal cell cancer or melanoma&#xD;
        Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-1 Life expectancy:&#xD;
        More than 3 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 90,000/mm3&#xD;
        No coagulation disorders Hepatic: Bilirubin no greater than 1.6 mg/dL AST and ALT less than&#xD;
        2.5 times normal Hepatitis B surface antigen negative Renal: Creatinine no greater than 2.0&#xD;
        mg/dL Cardiovascular: No major active medical illness of the cardiovascular system (e.g.,&#xD;
        cardiac ischemia, myocardial infarction, or cardiac arrhythmia) Pulmonary: No major active&#xD;
        medical illness of the respiratory system (e.g., obstructive or restrictive pulmonary&#xD;
        disease) Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use&#xD;
        effective contraception No active systemic infections No history of autoimmune disorders&#xD;
        HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy&#xD;
        No prior systemic flt3 ligand or CD40-ligand Chemotherapy: At least 3 weeks since prior&#xD;
        chemotherapy Endocrine therapy: At least 3 weeks since prior endocrine therapy No&#xD;
        concurrent systemic steroids Radiotherapy: Prior localized radiotherapy for renal cell&#xD;
        cancer or melanoma allowed Surgery: Prior surgery for renal cell cancer or melanoma allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Hwu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2002</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>April 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2004</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flt3 ligand protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

